The France flow cytometry market is expected to register growth during the forecast period owing to, technical development within the field of flow cytometry. In addition, increasing incidence of Cancer and HIV/AIDS, usage of flow cytometry in clinical trials, advent of application-specific flow cytometry products are further expected to provide growth platform to this market.
Flow cytometry is impedance-based, biophysical technology. It is used for cell counting & sorting, protein engineering, and detection of the biomarker by passing them by an electronic detection equipment and suspended cells in a fluid stream. It allows coincidental multipara-metric analysis of the chemical and physical characteristics of up to 1000 particles (per second).
Flow cytometry involves the analysis of the optical and visible light characteristics of a single particle (e.g. cells, nuclei, chromosomes) throughout their passage within a slender, specifically printed liquid stream. Measurement of cellular properties as they're obtaining a fluids stream.
France flow cytometry market has been segmented on the premise of technology, products & services, application, and finish used. On the premise of technology, the market has been segmented into cell-based and bead-based flow cytometry. On the premise of products & services offered by companies, the market has been segmented into instruments, reagents & consumables, accessories, software, and services.
This technology is used in pharmaceutical research for drug discovery, stem cell research, and in vitro toxicity testing studies. It also has applications in cell sorting, cell-cycle analysis, immunology, and cell viability studies. Flow cytometry is also used to detect cancer & immunodeficiency disorders, and in hematology, it is used for organ transplantation studies and in other applications.
Major market players in the flow cytometry market are Merck & Co., Inc., Sysmex Corporation, Beckman Coulter, Inc., Alere, Inc., Bio-Techne, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Miltenyi Biotec, Agilent Technologies, Inc., Becton, Dickinson and Company and Others.
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPR norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.